Rheumatology

General Dermatology

Questions discussed in this category

What is your approach to managing pyoderma gangrenosum recalcitrant to oral steroids?

When do you switch to steroid-sparing medications? What steroid-sparing therapies do you prefer?

6 Answers available

Does IVIG or subcutaneous Ig interfere with monoclonal antibody therapy (i.e. dupilumab, infliximab, rituximab, etc)?

How should IVIG and either biologic injections or infusions be spaced?

2 Answers available

What is your approach to evaluation in patients who present with erythromelalgia?

1 Answer available

How do you evaluate livedo reticularis (not livideo racemosa)?

Does your evaluation hinge on nonresolution with warming? How extensive is your workup?

1 Answer available

If you have clinical suspicion for a paraneoplastic process (e.g. dermatomyositis or pemphigus), what work-up do you pursue?

1 Answer available

Papers discussed in this category

Rheum Dis Clin North Am, 2020 Aug

Risk Factors and Cancer Screening in Myositis.

Rheumatology (Oxford),

A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies.

Clinical pharmacokinetics, 2018-12

Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease.

Frontiers in immunology, 2018

Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin.

Clinical immunology (Orlando, Fla.), 2020 Jul 15

The potential impact of timing of IVIG administration on the efficacy of rituximab for immune tolerance induction for patients with Pompe disease.

The Pediatric infectious disease journal, 2018 Oct

Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2017 Nov 03

Successful IVIG treatment without discontinuation of TNF-α blocker in Guillain-Barre syndrome induced by adalimumab in patient with Crohn's disease.

Related Topics in Rheumatology